カテゴリ： Global Markets Direct, 医療/バイオ

帯状疱疹（帯状疱疹）治療薬市場：パイプラインレビュー（2020年上半期）

◆英語タイトル：Herpes Zoster (Shingles) - Pipeline Review, H1 2020
◆商品コード：GDATA20MY0951
◆発行会社（リサーチ会社）：Global Markets Direct
◆発行日：2020年3月31日
◆ページ数：69
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,000 ⇒換算￥220,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD4,000 ⇒換算￥440,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD6,000 ⇒換算￥660,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

Herpes Zoster (Shingles) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) – Pipeline Review, H1 2020, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) – Overview
Herpes Zoster (Shingles) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) – Companies Involved in Therapeutics Development
Akshaya Bio Inc
Beijing Minhai Biotechnology Co Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
Herpes Zoster (Shingles) – Drug Profiles
B-1006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-016 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inflammatory Pain – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-400 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) – Dormant Projects
Herpes Zoster (Shingles) – Discontinued Products
Herpes Zoster (Shingles) – Product Development Milestones
Featured News & Press Releases
Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
Jan 30, 2020: NanoViricides confirms it has been working on a treatment for the novel Wuhan Coronavirus
Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 – HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Aug 26, 2019: NanoViricides advancing rapidly towards first IND
Aug 05, 2019: NanoViricides reports its first drug candidate is on track with GLP safety/toxicology studies toward human clinical trials
Jul 10, 2019: Shingles vaccine safely prevents outbreaks among stem cell transplant patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, H1 2020
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H1 2020
Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by GC Pharma, H1 2020
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2020
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2020
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2020
Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H1 2020
Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H1 2020
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2020
Herpes Zoster (Shingles) - Dormant Projects, H1 2020
Herpes Zoster (Shingles) - Discontinued Products, H1 2020

【掲載企業】

Akshaya Bio Inc
Beijing Minhai Biotechnology Co Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[帯状疱疹（帯状疱疹）治療薬市場：パイプラインレビュー（2020年上半期）]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 帯状疱疹（帯状疱疹）治療薬市場：パイプラインレビュー（2019年下半期）
    GDATA20MY0103 / Global Markets Direct / 2019年11月25日 / ...Herpes Zoster (Shingles) - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster - Pipeline Review, H2 2019, provides an overview of the Herpes Zoster (Infectious Disease) pipeline landscape. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster - Pipeline Review, H2 2019, provides comprehensive...
  2. ラッサ熱（ラッサ出血性熱）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0900 / Global Markets Direct / 2020年3月31日 / ...Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H1 2020, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide...
  3. 象皮病（リンパ系フィラリア症）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0745 / Global Markets Direct / 2020年1月31日 / ...Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape. Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics. Report Highlights Global Markets...
  4. 重症急性呼吸器症候群（SARS）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0855 / Global Markets Direct / 2020年2月28日 / ...Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS. Report Highlights Global Markets Direct's...
  5. 増殖性硝子体網膜症（PVR）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0877 / Global Markets Direct / 2020年2月28日 / ...Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape. Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline...
  6. 深部静脈血栓症（DVT）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0897 / Global Markets Direct / 2020年3月31日 / ...Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2020, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape. Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a...
  7. 慢性炎症性脱髄性多発ニューロパチー（CIDP）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0798 / Global Markets Direct / 2020年2月28日 / ...Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H1 2020, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape. Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness...
  8. 増殖性糖尿病性網膜症（PDR）治療薬市場：パイプラインレビュー（2020年上半期）
    GDATA20MY0952 / Global Markets Direct / 2020年3月31日 / ...Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2020, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆